EPHEDRINE KABI SOLUTION FOR INJECTION 30 MG/ML [SIN17621P]
Active ingredients: EPHEDRINE HYDROCHLORIDE
Product Info
EPHEDRINE KABI SOLUTION FOR INJECTION 30 MG/ML
[SIN17621P]
Product information
Active Ingredient and Strength | EPHEDRINE HYDROCHLORIDE - 30 MG/ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | LABESFAL - LABORATÓRIOS ALMIRO, S.A. - PORTUGAL |
Registration Number | SIN17621P |
Licence Holder | FRESENIUS KABI (SINGAPORE) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C01CA26 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
Reversal of anaesthesia induced hypotension during spinal and epidural anaesthesia.
Dosing
4.2 Posology and method of administration
Adults and the elderly:
Up to 30 mg in increments of 3 – 7.5 mg. After the development of hypotension, by slow intravenous administration.
Paediatric Population:
0.5 – 0.75 mg/kg body weight or 17 – 25 mg/m2 body surface. After the development of hypotension, by slow intravenous administration.
Method of Administration
Ephedrine must be used solely by or under the supervision of the anaesthetist as an injection via intravenous route.
The medicinal product should be diluted before use as applicable (see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
For intravenous use.
Contraindications
4.3 Contraindications
Ephedrine Kabi should not be used in case of:
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
In combination with other indirect sympathomimetic agents such as phenylpropanolamine, phenylephrine, pseudoephedrine and methylphenidate (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
In combination with alpha sympathomimetic agents (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
In combination with irreversible monoamine oxidase inhibitors (MAOI).
